Biondo Investment Advisors Has Cut Its Idexx Labs (IDXX) Stake as Valuation Rose; Americafirst Capital Management Lifted Its Hca Holdings (HCA) Stake

January 14, 2018 - By Henry Gaston

Americafirst Capital Management Llc increased its stake in Hca Holdings Inc (HCA) by 9.94% based on its latest 2017Q3 regulatory filing with the SEC. Americafirst Capital Management Llc bought 89 shares as the company’s stock declined 2.93% while stock markets rallied. The institutional investor held 984 shares of the health care company at the end of 2017Q3, valued at $78.32 million, up from 895 at the end of the previous reported quarter. Americafirst Capital Management Llc who had been investing in Hca Holdings Inc for a number of months, seems to be bullish on the $31.44B market cap company. The stock increased 2.10% or $1.83 during the last trading session, reaching $88.8. About 1.87 million shares traded. HCA Healthcare, Inc. (NYSE:HCA) has risen 7.08% since January 14, 2017 and is uptrending. It has underperformed by 9.62% the S&P500.

Biondo Investment Advisors Llc decreased its stake in Idexx Labs Inc (IDXX) by 5.15% based on its latest 2017Q3 regulatory filing with the SEC. Biondo Investment Advisors Llc sold 4,199 shares as the company’s stock rose 13.64% with the market. The institutional investor held 77,362 shares of the health care company at the end of 2017Q3, valued at $12.03M, down from 81,561 at the end of the previous reported quarter. Biondo Investment Advisors Llc who had been investing in Idexx Labs Inc for a number of months, seems to be less bullish one the $15.11 billion market cap company. The stock increased 1.01% or $1.73 during the last trading session, reaching $173.24. About 632,940 shares traded or 24.45% up from the average. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 83.30% since January 14, 2017 and is uptrending. It has outperformed by 66.60% the S&P500.

Since August 15, 2017, it had 0 buys, and 4 selling transactions for $719,075 activity.

Among 29 analysts covering HCA Holdings (NYSE:HCA), 20 have Buy rating, 2 Sell and 7 Hold. Therefore 69% are positive. HCA Holdings had 88 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, April 5 by Deutsche Bank. The firm earned “Outperform” rating on Thursday, August 6 by RBC Capital Markets. KeyBanc Capital Markets maintained HCA Healthcare, Inc. (NYSE:HCA) on Thursday, September 7 with “Buy” rating. The firm has “Neutral” rating given on Friday, October 2 by Citigroup. The stock of HCA Healthcare, Inc. (NYSE:HCA) earned “Buy” rating by Mizuho on Wednesday, October 4. The stock of HCA Healthcare, Inc. (NYSE:HCA) earned “Neutral” rating by JP Morgan on Wednesday, September 16. The firm has “Overweight” rating given on Thursday, October 8 by Barclays Capital. The firm has “Buy” rating given on Sunday, August 27 by RBC Capital Markets. The firm has “Buy” rating by Mizuho given on Friday, July 29. The rating was upgraded by JP Morgan to “Overweight” on Thursday, November 30.

Investors sentiment decreased to 0.79 in Q3 2017. Its down 0.09, from 0.88 in 2017Q2. It is negative, as 69 investors sold HCA shares while 180 reduced holdings. 54 funds opened positions while 143 raised stakes. 262.04 million shares or 0.29% more from 261.28 million shares in 2017Q2 were reported. Bremer Trust Natl Association owns 0.32% invested in HCA Healthcare, Inc. (NYSE:HCA) for 14,478 shares. Maryland-based Profit Invest Management Ltd Company has invested 0.32% in HCA Healthcare, Inc. (NYSE:HCA). Maverick Capital Ltd invested in 0.07% or 68,850 shares. Paw Cap reported 12,000 shares. Paloma Prtnrs Mgmt Com holds 0.01% or 7,872 shares in its portfolio. Euclidean Technologies Mgmt Lc holds 24,807 shares. Par Cap owns 2.00 million shares. 43 were accumulated by Tci Wealth. 7,966 are owned by Commonwealth Equity Svcs Inc. 596,358 were accumulated by Mitsubishi Ufj And Bk Corp. Americafirst Cap Lc owns 0.11% invested in HCA Healthcare, Inc. (NYSE:HCA) for 984 shares. Moreover, Investment House Ltd Liability Com has 0.08% invested in HCA Healthcare, Inc. (NYSE:HCA) for 7,975 shares. Hutchin Hill Capital Ltd Partnership reported 0.02% of its portfolio in HCA Healthcare, Inc. (NYSE:HCA). Qcm Cayman has 1.02% invested in HCA Healthcare, Inc. (NYSE:HCA) for 5,009 shares. Mutual Of America Capital Management Lc owns 35,732 shares.

Americafirst Capital Management Llc, which manages about $159.21M and $74.03 billion US Long portfolio, decreased its stake in Intel Corporation (NASDAQ:INTC) by 3,447 shares to 9,318 shares, valued at $354.83 million in 2017Q3, according to the filing. It also reduced its holding in Cigna Corporation (NYSE:CI) by 5,934 shares in the quarter, leaving it with 1,538 shares, and cut its stake in Target Corp.

Among 9 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 5 have Buy rating, 2 Sell and 2 Hold. Therefore 56% are positive. IDEXX Laboratories had 22 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Buy” rating by Stifel Nicolaus on Thursday, August 13. Bank of America reinitiated the shares of IDXX in report on Thursday, September 29 with “Neutral” rating. The company was maintained on Monday, August 21 by Canaccord Genuity. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Buy” rating by Stifel Nicolaus on Thursday, October 29. The rating was maintained by Stifel Nicolaus on Monday, October 23 with “Buy”. The company was maintained on Thursday, July 23 by Canaccord Genuity. The rating was initiated by CL King on Friday, April 1 with “Neutral”. Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Wednesday, July 20 with “Buy” rating. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, June 13 report. As per Monday, August 21, the company rating was maintained by Stifel Nicolaus.

Analysts await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings on February, 1. They expect $0.73 EPS, up 25.86% or $0.15 from last year’s $0.58 per share. IDXX’s profit will be $63.67 million for 59.33 P/E if the $0.73 EPS becomes a reality. After $0.79 actual EPS reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts -7.59% negative EPS growth.

Since August 8, 2017, it had 0 buys, and 5 insider sales for $17.16 million activity. The insider HENDERSON REBECCA M sold $790,342.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: